January 30, 2006 -- ISTA Pharma reported that the FDA expanded the indications for Xibrom to include pain after cataract surgery; Inspire Pharma will begin a Phase III trial of its cystic fibrosis drug; Watson Pharma received FDA approval for a generic version of AndroGel, a testosterone therapy developed by Solvay Pharma; vaccine maker Iomai cut both the size and price of its IPO; CytRx will spin off its RNAi development efforts into a new company; Schering Plough won Fast Track status for SCH 503034, a hepatititis C drug; Adventrx Pharma reported positive data for CoFactor, its metastatic colorectal cancer drug; and Bayer in-licensed two diagnostic tests from Abbott Labs. The Centient Biotech 200™ was down 19 points at 3924.30, a drop of .48%. More details...
